Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
80 hedge funds and large institutions have $314M invested in Cymabay Therapeutics in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 10 closing their positions.
166% more call options, than puts
Call options by funds: $393K | Put options by funds: $148K
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $244M → $314M (+$69.4M)
25% more funds holding
Funds holding: 64 → 80 (+16)
11% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.4M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$5.04M |
| 3 |
NC
Nexthera Capital
New York
|
+$4.46M |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$3.67M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$3.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.03M |
| 3 |
A
Abingworth
London,
United Kingdom
|
-$3.38M |
| 4 |
Renaissance Technologies
New York
|
-$3.21M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.23M |
CBAY Hedge Fund Activity: Q4 2017 in Review
80 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2017, worth a combined $314M — up 28% from $244M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CBAY positions and 10 closed out — a net gain of 16 holders — while 20 added to existing stakes and 18 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $9.4M. The largest seller was Millennium Management, cutting an estimated $14M.
- 80 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2017, up from 64 in Q3 2017.
- Funds reported $314M of Cymabay Therapeutics stock for Q4 2017, up 28% quarter-over-quarter.
- 26 funds opened new Cymabay Therapeutics positions in Q4 2017 and 10 closed out, a net change of +16 holders.
- The largest Cymabay Therapeutics buyer in Q4 2017 was Farallon Capital Management, an estimated $9.4M added.
- The largest Cymabay Therapeutics seller in Q4 2017 was Millennium Management, an estimated $14M sold.
Based on aggregated 13F filings for Q4 2017.